Nahdi Medical Company (TADAWUL:4164)
Saudi Arabia · Delayed Price · Currency is SAR 91.70
-0.90 (-0.97%)
Sep 3, 2026, 3:19 PM AST
Nahdi Medical Company Ratios and Metrics
Market cap in millions SAR. Fiscal year is January - December.
Millions SAR. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 11,921 | 12,350 | 15,288 | 17,810 | 21,736 | - | |
Market Cap Growth | -21.56% | -19.22% | -14.16% | -18.06% | - | - |
Enterprise Value | 13,167 | 13,511 | 16,025 | 17,991 | 22,301 | - |
Last Close Price | 91.70 | 89.83 | 106.03 | 118.72 | 140.13 | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 15.13 | 14.87 | 18.63 | 19.95 | 24.48 | - |
Forward PE | 13.93 | 14.12 | 17.51 | 20.42 | 23.26 | - |
PS Ratio | 1.13 | 1.21 | 1.62 | 2.04 | 2.52 | - |
PB Ratio | 4.75 | 4.50 | 5.91 | 7.23 | 9.69 | - |
P/TBV Ratio | 4.87 | 4.62 | 6.07 | 7.39 | 9.90 | - |
P/FCF Ratio | 10.14 | 16.54 | 13.27 | 18.51 | 15.33 | - |
P/OCF Ratio | 7.77 | 10.89 | 10.25 | 13.53 | 13.03 | - |
PEG Ratio | 3.43 | 3.07 | 6.95 | 6.59 | 3.46 | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 1.25 | 1.32 | 1.70 | 2.07 | 2.59 | - |
EV/EBITDA Ratio | 7.83 | 11.12 | 14.18 | 15.24 | 18.71 | - |
EV/EBIT Ratio | 14.61 | 14.59 | 18.38 | 18.73 | 22.31 | - |
EV/FCF Ratio | 11.20 | 18.10 | 13.91 | 18.70 | 15.73 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.70 | 0.65 | 0.59 | 0.48 | 0.52 | 0.85 |
Debt / EBITDA Ratio | 1.04 | 1.06 | 0.99 | 0.76 | 0.74 | 0.93 |
Debt / FCF Ratio | 1.49 | 2.39 | 1.33 | 1.22 | 0.82 | 1.29 |
Net Debt / Equity Ratio | 0.50 | 0.45 | 0.22 | 0.11 | 0.04 | 0.60 |
Net Debt / EBITDA Ratio | 1.04 | 1.01 | 0.51 | 0.23 | 0.08 | 0.90 |
Net Debt / FCF Ratio | 1.06 | 1.65 | 0.50 | 0.28 | 0.07 | 0.91 |
Asset Turnover | 1.59 | 1.59 | 1.64 | 1.69 | 1.87 | 1.80 |
Inventory Turnover | 3.36 | 3.27 | 3.86 | 4.07 | 4.47 | 4.26 |
Quick Ratio | 0.32 | 0.38 | 0.55 | 0.66 | 0.80 | 0.42 |
Current Ratio | 1.28 | 1.54 | 1.54 | 1.69 | 1.70 | 1.40 |
Return on Equity (ROE) | 30.31% | 31.17% | 32.51% | 37.93% | 46.16% | 44.13% |
Return on Assets (ROA) | 8.53% | 9.00% | 9.44% | 11.64% | 13.54% | 12.65% |
Return on Invested Capital (ROIC) | 25.11% | 25.50% | 29.12% | 35.88% | 38.65% | 35.28% |
Return on Capital Employed (ROCE) | 21.20% | 20.40% | 20.90% | 25.70% | 29.10% | 30.20% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 6.61% | 6.73% | 5.37% | 5.01% | 4.08% | - |
FCF Yield | 9.86% | 6.05% | 7.53% | 5.40% | 6.52% | - |
Dividend Yield | 6.11% | 6.23% | 5.19% | 4.63% | 3.79% | - |
Payout Ratio | 92.38% | 87.63% | 87.12% | 80.10% | 33.83% | 155.07% |
Total Shareholder Return | 6.11% | 6.23% | 5.19% | 4.63% | 3.79% | - |